Blog
RSS FeedPosted by Michael Wonder on 28 Feb 2023
“Killing time” one year on, still no final response from PHARMAC to the independent review
28 February 2023 - Today marks one year since the PHARMAC Review was delivered to then Health Minister Andrew Little. ...
Posted by Michael Wonder on 27 Feb 2023
PHARMAC shares the agenda items for the upcoming Rare Disorders Committee meeting
27 February 2023 - PHARMAC is creating visibility of what medicines are being considered that could impact the rare disorders ...
Posted by Michael Wonder on 21 Feb 2023
PHARMAC's communications approach for the Trikafta consultation
21 February 2023 - To be transparent about its approach, PHARMAC has released information, including a communications plan and correspondence ...
Posted by Michael Wonder on 10 Feb 2023
PHARMAC to get one time $66 million boost
10 February 2023 - The national drug-buying agency will get an extra $66 million in 2023 in a one-off cash ...
Posted by Michael Wonder on 31 Jan 2023
New Zealand Pharmaceutical Schedule - 1 February 2023
1 February 2023 - The February 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 22 Jan 2023
Pharmaceuticals campaigner moving to Australia after drug she desperately needs for spinal muscular atrophy is only funded for under 18s
22 January 2023 - This week, PHARMAC announced it was looking to fund a second drug to treat the neurological ...
Posted by Michael Wonder on 18 Jan 2023
PHARMAC seeking feedback on funding a second spinal muscular atrophy treatment
19 January 2023 - PHARMAC is initiating a consultation today, seeking feedback on a proposal to fund of risdiplam (Evrysdi) for ...
Posted by Michael Wonder on 15 Jan 2023
PHARMAC's year in review leaves much to be desired
1 January 2023 - Christmas came early for a number of long-suffering patients. ...
Posted by Michael Wonder on 19 Dec 2022
PHARMAC funds more treatments for people with inflammatory bowel disease
20 December 2022 - Pharmac has today announced funding of ustekinumab (Stelara) for people with inflammatory bowel disease (IBD) and ...
Posted by Michael Wonder on 19 Dec 2022
Allergy advocate group 'absolutely delighted' after PHARMAC announces full funding for EpiPen auto-injectors
15 December 2022 - Aotearoa's drug buying agency has announced it will fully fund the EpiPen brand of adrenaline auto-injectors ...
Posted by Michael Wonder on 15 Dec 2022
PHARMAC consulting on two new medicines for lung cancer
16 December 2022 - PHARMAC has reached provisional agreements with two different suppliers to fund two medicines to treat New Zealanders ...
Posted by Michael Wonder on 15 Dec 2022
Children, parents protest PHARMAC funding review at Parliament
14 December 2022 - A petition calling on PHARMAC to "fund lifesaving medicines for all New Zealand children" has been ...
Posted by Michael Wonder on 14 Dec 2022
PHARMAC to fund the EpiPen for severe allergies
15 December 2022 - PHARMAC has confirmed today that it will be fully funding the EpiPen brand of adrenaline auto ...
Posted by Michael Wonder on 13 Dec 2022
PHARMAC petition: fear tamariki with cancer won’t have access to lifesaving medicines
13 December 2022 - A petition, that will be delivered tomorrow to Parliament, on behalf of Tamariki with cancer, chronic ...
Posted by Michael Wonder on 11 Dec 2022
Miracle medicines: a cancer specialist sends a message to PHARMAC
11 December 2022 - Let's make one thing crystal clear: effective chemotherapeutic drugs make a tremendous difference to survival outcomes ...